Published: 8 June 2020
Author(s): Gregorio Paolo Milani, Emanuele Montomoli, Valentina Bollati, On behalf of the UNICORN Consortium investigators, Benedetta Albetti, Claudio Bandi, Tommaso Bellini, Matteo Bonzini, Marco Buscaglia, Carlo Cantarella, Laura Cantone, Michele Carugno, Sergio Casartelli, Guido Cavaletti, Sarah D'Alessandro, Francesca De Chiara, Serena Delbue, Laura Dioni, Ivano Eberini, Chiara Favero, Luca Ferrari, Monica Ferraroni, Laura Galastri, Cristina Galli, Mirjam Hoxha, Simona Iodice, Carlo La Vecchia, Chiara Macchi, Ilaria Manini, Serena Marchi, Jacopo Mariani, Elena Pariani, Angela Cecilia Pesatori, Federica Rota, Massimiliano Ruscica, Tommaso Schioppo, Letizia Tarantini, Claudia Maria Trombetta, Maria Grazia Valsecchi, Marco Vicenzi, Giuliano Zanchetta
Section: Letter to the Editor
At the end of December 2019, the first cases of SARS-CoV-2 infection were identified in Wuhan, China. [1] In the following months, the outbreak of SARS-COV-2 infections spreads worldwide [1] As of May 1, 2020, more than 3 million of SARS-CoV-2 infections have been detected worldwide. These data were mainly collected from inpatients. On the other hand, asymptomatic or mildly symptomatic subjects are usually untested for SARS-CoV-2 although they are supposed to far outnumber the symptomatic patients.
